

Namiki Izumi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2421195/publications.pdf>

Version: 2024-02-01

126
papers

7,918
citations

87723

38
h-index

53109

85
g-index

126
all docs

126
docs citations

126
times ranked

6670
citing authors

#	ARTICLE	IF	CITATIONS
1	Two-Step Strategy, FIB-4 Followed by Magnetic Resonance Elastography, for Detecting Advanced Fibrosis in NAFLD. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 380-387.e3.	2.4	10
2	Hepatocellular Carcinoma Risk Assessment for Patients With Advanced Fibrosis After Eradication of Hepatitis C Virus. <i>Hepatology Communications</i> , 2022, 6, 461-472.	2.0	10
3	Letter: association of laboratory indexes and magnetic resonance elastography-associated liver stiffness with complications and mortality—authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 626-627.	1.9	0
4	Longitudinal association of magnetic resonance elastography-associated liver stiffness with complications and mortality. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 292-301.	1.9	38
5	The impact of background liver disease on the long-term prognosis of very-early-stage HCC after ablation therapy. <i>PLoS ONE</i> , 2022, 17, e0264075.	1.1	2
6	Clinical usefulness of geriatric assessment in elderly patients with unresectable hepatocellular carcinoma receiving sorafenib or lenvatinib therapy. <i>Cancer Reports</i> , 2022, 5, e1613.	0.6	4
7	Clinical evaluation of Elecsys PIVKA-II for patients with advanced hepatocellular carcinoma. <i>PLoS ONE</i> , 2022, 17, e0265235.	1.1	4
8	A validation study of after direct-acting antiviral recommendation for surveillance score for the development of hepatocellular carcinoma in patients with hepatitis C virus infection who had received direct-acting antiviral therapy and achieved sustained virological response. <i>JGH Open</i> , 2022, 6, 20-28.	0.7	4
9	Conversion surgery for hepatocellular carcinoma after tyrosine kinase inhibitor treatment. <i>JGH Open</i> , 2022, 6, 301-308.	0.7	7
10	Validation of magnetic resonance elastography plus FIB-4 for significant fibrosis in nonalcoholic fatty liver disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2022, , .	1.4	1
11	<scp>General evaluation score</scp> for predicting the development of <scp>hepatocellular carcinoma</scp> in patients with advanced liver fibrosis associated with <scp>hepatitis C virus</scp> genotype 1 or 2 after <scp>direct-acting antiviral</scp> therapy. <i>JGH Open</i> , 2022, 6, 487-495.	0.7	0
12	Real-World Data on Ramucirumab Therapy including Patients Who Experienced Two or More Systemic Treatments: A Multicenter Study. <i>Cancers</i> , 2022, 14, 2975.	1.7	5
13	Current status of primary liver cancer and decompensated cirrhosis in Japan: launch of a nationwide registry for advanced liver diseases (REAL). <i>Journal of Gastroenterology</i> , 2022, 57, 587-597.	2.3	5
14	Clinical validation of an immunochromatographic SARS-CoV-2 IgM/IgG antibody assay with Japanese cohort. <i>Journal of Medical Virology</i> , 2021, 93, 569-572.	2.5	12
15	Changes of liver stiffness measured by magnetic resonance elastography during direct-acting antiviral treatment in patients with chronic hepatitis C. <i>Journal of Medical Virology</i> , 2021, 93, 3744-3751.	2.5	8
16	Clinical Utility of Mac-2 Binding Protein Glycosylation Isomer in Chronic Liver Diseases. <i>Annals of Laboratory Medicine</i> , 2021, 41, 16-24.	1.2	27
17	Dynamic evaluation of hepatocellular carcinoma prediction models in patients with chronic hepatitis B receiving nucleotide/nucleoside analogue treatment. <i>Journal of Viral Hepatitis</i> , 2021, 28, 787-794.	1.0	7
18	Change in Fibrosis 4 Index as Predictor of High Risk of Incident Hepatocellular Carcinoma After Eradication of Hepatitis C Virus. <i>Clinical Infectious Diseases</i> , 2021, 73, e3349-e3354.	2.9	21

#	ARTICLE	IF	CITATIONS
19	Assessing the periprocedural magnitude of platelet count change in response to lusutrombopag. JHEP Reports, 2021, 3, 100228.	2.6	7
20	The Real-World Data in Japanese Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib from a Nationwide Multicenter Study. Cancers, 2021, 13, 2608.	1.7	34
21	Management of Hepatocellular Carcinoma in Japan: JSH Consensus Statements and Recommendations 2021 Update. Liver Cancer, 2021, 10, 181-223.	4.2	307
22	Hepatitis B core-related antigen predicts disease progression and hepatocellular carcinoma in hepatitis B e antigen-negative chronic hepatitis B patients. Journal of Gastroenterology and Hepatology (Australia), 2021, 36, 2943-2951.	1.4	11
23	Prognosis of intrahepatic cholangiocarcinoma stratified by albumin-bilirubin grade. Hepatology Research, 2021, 51, 902-908.	1.8	11
24	Attenuation coefficient (ATT) measurement for liver fat quantification in chronic liver disease. Journal of Medical Ultrasonics (2001), 2021, 48, 481-487.	0.6	11
25	Reply to Wang et al. Journal of Viral Hepatitis, 2021, 28, 1335-1336.	1.0	0
26	Liver fibrosis and fatty liver as independent risk factors for cardiovascular disease. Journal of Gastroenterology and Hepatology (Australia), 2021, 36, 2960-2966.	1.4	36
27	Real-world clinical outcomes of sofosbuvir and velpatasvir treatment in HCV genotype 1 and 2 infected patients with decompensated cirrhosis: A nationwide multicenter study by the Japanese Red Cross Liver Study Group. Journal of Medical Virology, 2021, 93, 6247-6256.	2.5	16
28	The dynamics of quantitative SARS-CoV-2 antispike IgG response to BNT162b2 vaccination. Journal of Medical Virology, 2021, 93, 6813-6817.	2.5	8
29	Tenofovir alafenamide for prevention and treatment of hepatitis B virus reactivation and de novo hepatitis. JGH Open, 2021, 5, 1085-1091.	0.7	5
30	Wisteria floribunda Agglutinin-Positive Mac-2 Binding Protein as a Screening Tool for Significant Liver Fibrosis in Health Checkup. International Journal of Molecular Sciences, 2021, 22, 40.	1.8	8
31	Diagnostic accuracy of hepatocellular carcinoma risk prediction models during antiviral therapy in chronic hepatitis B patients. Hepatology Research, 2021, 51, 1170-1171.	1.8	0
32	Three criteria for radiological response on survival in patients with hepatocellular carcinoma treated with lenvatinib. Hepatology Research, 2020, 50, 137-143.	1.8	19
33	Report of the 20th Nationwide follow-up survey of primary liver cancer in Japan. Hepatology Research, 2020, 50, 15-46.	1.8	111
34	Hepatitis B surface antigen reduction as a result of switching from long-term entecavir administration to tenofovir. JGH Open, 2020, 4, 429-432.	0.7	11
35	Is platelet monitoring during 7-day lusutrombopag treatment necessary in chronic liver disease patients with thrombocytopenia undergoing planned invasive procedures? A phase IIIb open-label study. Hepatology Research, 2020, 50, 1141-1150.	1.8	4
36	Detectable HBV DNA during nucleos(t)ide analogues stratifies predictive hepatocellular carcinoma risk score. Scientific Reports, 2020, 10, 13021.	1.6	8

#	ARTICLE	IF	CITATIONS
37	Strategy for advanced hepatocellular carcinoma based on liver function and portal vein tumor thrombosis. <i>Hepatology Research</i> , 2020, 50, 1375-1385.	1.8	22
38	Impaired brain function improved by l-carnitine in patients with cirrhosis: evaluation using near-infrared spectroscopy. <i>Scientific Reports</i> , 2020, 10, 13566.	1.6	6
39	Early radiological response evaluation with response evaluation criteria in solid tumors 1.1 stratifies survival in hepatocellular carcinoma patients treated with lenvatinib. <i>JGH Open</i> , 2020, 4, 1183-1190.	0.7	6
40	Wisteria floribunda Agglutinin-Positive Mac-2 Binding Protein but not Î±-fetoprotein as a Long-Term Hepatocellular Carcinoma Predictor. <i>International Journal of Molecular Sciences</i> , 2020, 21, 3640.	1.8	5
41	Validation of albumin, bilirubin, and platelet criteria for avoiding screening endoscopy in patients with advanced fibrosis. <i>Hepatology Research</i> , 2020, 50, 996-999.	1.8	5
42	Features of resistance-associated substitutions after failure of multiple direct-acting antiviral regimens for hepatitis C. <i>JHEP Reports</i> , 2020, 2, 100138.	2.6	10
43	Validation of hepatocellular carcinoma risk scores in Japanese chronic hepatitis B cohort receiving nucleot(s)ide analog. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020, 35, 1595-1601.	1.4	18
44	Comparison of medication adherence and satisfaction between entecavir and tenofovir alafenamide therapy in chronic hepatitis B. <i>Journal of Medical Virology</i> , 2020, 92, 1355-1358.	2.5	16
45	Use of the Serum Wisteria floribunda Agglutinin-Positive Mac2 Binding Protein as a Marker of Gastroesophageal Varices and Liver-Related Events in Chronic Hepatitis C Patients. <i>Diagnostics</i> , 2020, 10, 173.	1.3	8
46	Relative dose intensity over the first four weeks of lenvatinib therapy is a factor of favorable response and overall survival in patients with unresectable hepatocellular carcinoma. <i>PLoS ONE</i> , 2020, 15, e0231828.	1.1	42
47	Liver injury with COVID-19 based on gastrointestinal symptoms and pneumonia severity. <i>PLoS ONE</i> , 2020, 15, e0241663.	1.1	10
48	A randomized controlled trial of lusutrombopag in Japanese patients with chronic liver disease undergoing radiofrequency ablation. <i>Journal of Gastroenterology</i> , 2019, 54, 171-181.	2.3	67
49	Lenvatinib as an Initial Treatment in Patients with Intermediate-Stage Hepatocellular Carcinoma Beyond Up-To-Seven Criteria and Childâ€™Pugh A Liver Function: A Proof-Of-Concept Study. <i>Cancers</i> , 2019, 11, 1084.	1.7	200
50	Wisteria floribunda agglutinin-positive mac-2 binding protein as an age-independent fibrosis marker in nonalcoholic fatty liver disease. <i>Scientific Reports</i> , 2019, 9, 10109.	1.6	24
51	Clinical practice guidelines for hepatocellular carcinoma: The Japan Society of Hepatology 2017 (4th) Tj ETQq1 1 0.784314 rgBT /Overlo	1.8	399
52	Sorafenib-Regorafenib Sequential Therapy in Japanese Patients with Unresectable Hepatocellular Carcinomaâ€™Relative Dose Intensity and Post-Regorafenib Therapies in Real World Practice. <i>Cancers</i> , 2019, 11, 1517.	1.7	30
53	New diagnostic technique to evaluate hepatic steatosis using the attenuation coefficient on ultrasound B mode. <i>PLoS ONE</i> , 2019, 14, e0221548.	1.1	29
54	Baseline and Early Predictors of Good Patient Candidates for Second-Line after Sorafenib Treatment in Unresectable Hepatocellular Carcinoma. <i>Cancers</i> , 2019, 11, 1256.	1.7	17

#	ARTICLE	IF	CITATIONS
55	Reply. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 1419-1420.	2.4	0
56	Efficacy and safety of glecaprevir/pibrentasvir as retreatment therapy for patients with genotype 2 chronic hepatitis C who failed prior sofosbuvir plus ribavirin regimen. <i>Hepatology Research</i> , 2019, 49, 1121-1126.	1.8	8
57	Real-world efficacy of elbasvir and grazoprevir for hepatitis C virus (genotype 1): A nationwide, multicenter study by the Japanese Red Cross Hospital Liver Study Group. <i>Hepatology Research</i> , 2019, 49, 1114-1120.	1.8	17
58	Tenofovir alafenamide for hepatitis B virus infection including switching therapy from tenofovir disoproxil fumarate. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2019, 34, 2004-2010.	1.4	48
59	Prediction of Hepatocellular Carcinoma After Sustained Virological Responses Using Magnetic Resonance Elastography. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 2616-2618.	2.4	17
60	Lusutrombopag Reduces Need for Platelet Transfusion in Patients With Thrombocytopenia Undergoing Invasive Procedures. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 1192-1200.	2.4	92
61	Risk assessment of hepatocellular carcinoma development by magnetic resonance elastography in chronic hepatitis C patients who achieved sustained virological responses by direct-acting antivirals. <i>Journal of Viral Hepatitis</i> , 2019, 26, 893-899.	1.0	25
62	Real-life experience of lusutrombopag for cirrhotic patients with low platelet counts being prepared for invasive procedures. <i>PLoS ONE</i> , 2019, 14, e0211122.	1.1	23
63	IDDF2019-ABS-0168... Bone and renal safety are improved in chronic hbv patients 1 year after switching to tenofovir alafenamide (TAF) from tenofovir disoproxil fumarate (TDF). , 2019, , .		0
64	Objective Response by mRECIST Is an Independent Prognostic Factor for Overall Survival in Hepatocellular Carcinoma Treated with Sorafenib in the SILIUS Trial. <i>Liver Cancer</i> , 2019, 8, 505-519.	4.2	20
65	Real-world efficacy and safety of sofosbuvir + ribavirin for hepatitis C genotype 2: A nationwide multicenter study by the Japanese Red Cross Liver Study Group. <i>Hepatology Research</i> , 2019, 49, 264-270.	1.8	27
66	Non-invasive liver fibrosis assessment correlates with collagen and elastic fiber quantity in patients with hepatitis C virus infection. <i>Hepatology Research</i> , 2019, 49, 33-41.	1.8	22
67	Mechanisms and Treatment for Muscle Cramps in Liver Cirrhosis. , 2019, , 141-149.		0
68	Efficacy of daclatasvir plus asunaprevir in patients with hepatitis C virus infection undergoing and not undergoing hemodialysis. <i>Hepatology Research</i> , 2018, 48, 746-756.	1.8	11
69	Novel quantitative assessment system of liver steatosis using a newly developed attenuation measurement method. <i>Hepatology Research</i> , 2018, 48, 821-828.	1.8	74
70	Real-world efficacy and safety of ledipasvir and sofosbuvir in patients with hepatitis C virus genotype 1 infection: a nationwide multicenter study by the Japanese Red Cross Liver Study Group. <i>Journal of Gastroenterology</i> , 2018, 53, 1142-1150.	2.3	36
71	Sorafenib plus low-dose cisplatin and fluorouracil hepatic arterial infusion chemotherapy versus sorafenib alone in patients with advanced hepatocellular carcinoma (SILIUS): a randomised, open label, phase 3 trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2018, 3, 424-432.	3.7	216
72	96-weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection. <i>Journal of Hepatology</i> , 2018, 68, 672-681.	1.8	291

#	ARTICLE	IF	CITATIONS
73	Upâ€toâ€seven criteria as a useful predictor for tumor downstaging to within Milan criteria and Childâ€Pugh grade deterioration after initial conventional transarterial chemoembolization. Hepatology Research, 2018, 48, 442-450.	1.8	49
74	Response criteria of tolvaptan for the treatment of hepatic edema. Journal of Gastroenterology, 2018, 53, 258-268.	2.3	27
75	IDDF2018-ABS-0110â€...Efficacy and safety of SOFOSBUVIR/VELPATASVIR plus RIBAVIRIN for 12 or 24 weeks in genotype 1 or 2 HCV-INFECTED Japanese patients with prior treatment failure to daa-based regimens. , 2018, , .		0
76	Sofosbuvirâ€velpatasvir plus ribavirin in Japanese patients with genotype 1 or 2 hepatitis C who failed direct-acting antivirals. Hepatology International, 2018, 12, 356-367.	1.9	41
77	<i>Wisteria floribunda</i> agglutininâ€positive Macâ€2 binding protein predicts early occurrence of hepatocellular carcinoma after sustained virologic response by directâ€acting antivirals for hepatitis C virus. Hepatology Research, 2018, 48, 1131-1139.	1.8	40
78	No Resistance to Tenofovir Alafenamide Detected through 96 Weeks of Treatment in Patients with Chronic Hepatitis B Infection. Antimicrobial Agents and Chemotherapy, 2018, 62, .	1.4	41
79	Impact of pre-sarcopenia in sorafenib treatment for advanced hepatocellular carcinoma. PLoS ONE, 2018, 13, e0198812.	1.1	51
80	Serum Wisteria Floribunda Agglutinin-Positive Sialylated Mucin 1 as a Marker of Progenitor/Biliary Features in Hepatocellular Carcinoma. Scientific Reports, 2017, 7, 244.	1.6	14
81	Diagnosis of Fibrosis and Activity by a Combined Use of Strain and Shear Wave Imaging in Patients with Liver Disease. Digestive Diseases, 2017, 35, 515-520.	0.8	36
82	Validation and Potential of Albumin-Bilirubin Grade and Prognostication in a Nationwide Survey of 46,681 Hepatocellular Carcinoma Patients in Japan: The Need for a More Detailed Evaluation of Hepatic Function. Liver Cancer, 2017, 6, 325-336.	4.2	202
83	Prediction of diuretic response to tolvaptan by a simple, readily available spot urine Na/K ratio. PLoS ONE, 2017, 12, e0174649.	1.1	24
84	Pretreatment Gastric Lavage Reduces Postoperative Bleeding after Endoscopic Submucosal Dissection for Gastric Neoplasms. PLoS ONE, 2016, 11, e0149235.	1.1	5
85	Complex Pattern of Resistance-Associated Substitutions of Hepatitis C Virus after Daclatasvir/Asunaprevir Treatment Failure. PLoS ONE, 2016, 11, e0165339.	1.1	36
86	Effects of antiviral therapy for hepatitis C following treatment of hepatocellular carcinoma: survey findings of the Japanese Red Cross Liver Study Group. Hepatology Research, 2016, 46, 251-258.	1.8	12
87	Tolvaptan for the Treatment of Refractory Ascites. Internal Medicine, 2016, 55, 2909-2910.	0.3	1
88	Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. The Lancet Gastroenterology and Hepatology, 2016, 1, 196-206.	3.7	377
89	Proposal of a new staging system for intrahepatic cholangiocarcinoma: Analysis of surgical patients from a nationwide survey of the Liver Cancer Study Group of Japan. Cancer, 2016, 122, 61-70.	2.0	132
90	Survival benefit of liver resection for hepatocellular carcinoma associated with portal vein invasion. Journal of Hepatology, 2016, 65, 938-943.	1.8	354

#	ARTICLE	IF	CITATIONS
91	Urinary excretion of the water channel aquaporin ² correlated with the pharmacological effect of tolvaptan in cirrhotic patients with ascites. <i>Journal of Gastroenterology</i> , 2016, 51, 620-627.	2.3	36
92	Elastin Fiber Accumulation in Liver Correlates with the Development of Hepatocellular Carcinoma. <i>PLoS ONE</i> , 2016, 11, e0154558.	1.1	34
93	Proposal of Japan Red Cross score for sorafenib therapy in hepatocellular carcinoma. <i>Hepatology Research</i> , 2015, 45, E130-40.	1.8	13
94	Naturally occurring, resistance-associated hepatitis C virus NS5A variants are linked to interleukin ^{28B} genotype and are sensitive to interferon-based therapy. <i>Hepatology Research</i> , 2015, 45, E115-21.	1.8	37
95	<i>Wisteria floribunda</i> agglutinin positive human Mac ² binding protein as a predictor of hepatocellular carcinoma development in chronic hepatitis C patients. <i>Hepatology Research</i> , 2015, 45, E82-8.	1.8	55
96	Non-alcoholic fatty liver disease fibrosis score and ^{FIB-4} scoring system could identify patients at risk of systemic complications. <i>Hepatology Research</i> , 2015, 45, 667-675.	1.8	26
97	Risk of hepatocellular carcinoma in cirrhotic hepatitis ^B virus patients during nucleoside/nucleotide analog therapy. <i>Hepatology Research</i> , 2015, 45, 872-879.	1.8	26
98	Genetic Polymorphisms of IL28B and PNPLA3 Are Predictive for HCV Related Rapid Fibrosis Progression and Identify Patients Who Require Urgent Antiviral Treatment with New Regimens. <i>PLoS ONE</i> , 2015, 10, e0137351.	1.1	22
99	Resistance-Associated NS5A Variants of Hepatitis C Virus Are Susceptible to Interferon-Based Therapy. <i>PLoS ONE</i> , 2015, 10, e0138060.	1.1	18
100	Safety and efficacy of tigatuzumab plus sorafenib as first-line therapy in subjects with advanced hepatocellular carcinoma: A phase 2 randomized study. <i>Journal of Hepatology</i> , 2015, 63, 896-904.	1.8	44
101	Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naïve and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trial. <i>Lancet Infectious Diseases</i> , The, 2015, 15, 645-653.	4.6	333
102	Evidence-based ^C linical ^P ractice ^G uidelines for ^H epatocellular ^C arcinoma: The ^J apan ^S ociety of ^H epatology 2013 update (3rd ^{JSH-HCC G} uidelines). <i>Hepatology Research</i> , 2015, 45,	1.8	339
103	Clinical features associated with radiological response to sorafenib in unresectable hepatocellular carcinoma: a large multicenter study in Japan. <i>Liver International</i> , 2015, 35, 1581-1589.	1.9	30
104	L-carnitine Reduces Muscle Cramps in Patients With Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 1540-1543.	2.4	53
105	JSH Consensus-Based Clinical Practice Guidelines for the Management of Hepatocellular Carcinoma: 2014 Update by the Liver Cancer Study Group of Japan. <i>Liver Cancer</i> , 2014, 3, 458-468.	4.2	512
106	Efficacy of daclatasvir in hepatitis C virus. <i>Expert Review of Anti-Infective Therapy</i> , 2014, 12, 1025-1031.	2.0	11
107	Changes in plasma vascular endothelial growth factor at 8 weeks after sorafenib administration as predictors of survival for advanced hepatocellular carcinoma. <i>Cancer</i> , 2014, 120, 229-237.	2.0	57
108	Sofosbuvir plus ribavirin in Japanese patients with chronic genotype 2 ^{HCV} infection: an open-label, phase 3 trial. <i>Journal of Viral Hepatitis</i> , 2014, 21, 762-768.	1.0	191

#	ARTICLE	IF	CITATIONS
109	Impaired brain activity in cirrhotic patients with minimal hepatic encephalopathy: Evaluation by near-infrared spectroscopy. <i>Hepatology Research</i> , 2014, 44, 319-326.	1.8	12
110	Non-invasive prediction of hepatocellular carcinoma development using serum fibrosis marker in chronic hepatitis C patients. <i>Journal of Gastroenterology</i> , 2014, 49, 1495-1503.	2.3	44
111	Simeprevir with peginterferon/ribavirin for treatment-naïve hepatitis C genotype 1 patients in Japan: CONCERTO-1, a phase III trial. <i>Journal of Hepatology</i> , 2014, 61, 219-227.	1.8	135
112	Once-daily simeprevir with peginterferon and ribavirin for treatment-experienced HCV genotype 1-infected patients in Japan: the CONCERTO-2 and CONCERTO-3 studies. <i>Journal of Gastroenterology</i> , 2014, 49, 941-953.	2.3	96
113	Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection. <i>Hepatology</i> , 2014, 59, 2083-2091.	3.6	517
114	Prospective comparison of real-time tissue elastography and serum fibrosis markers for the estimation of liver fibrosis in chronic hepatitis C patients. <i>Hepatology Research</i> , 2014, 44, 720-727.	1.8	22
115	Multicenter Study of Pegylated Interferon α 2a Monotherapy for Hepatitis C Virus-Infected Patients on Hemodialysis: REACH Study. <i>Therapeutic Apheresis and Dialysis</i> , 2014, 18, 603-611.	0.4	17
116	Comparison of resection and ablation for hepatocellular carcinoma: A cohort study based on a Japanese nationwide survey. <i>Journal of Hepatology</i> , 2013, 58, 724-729.	1.8	322
117	Quantification of collagen and elastic fibers using whole-slide images of liver biopsy specimens. <i>Pathology International</i> , 2013, 63, 305-310.	0.6	34
118	α -fetoprotein levels after interferon therapy and risk of hepatocarcinogenesis in chronic hepatitis C. <i>Hepatology</i> , 2013, 58, 1253-1262.	3.6	227
119	Expression of Keratin 19 Is Related to High Recurrence of Hepatocellular Carcinoma after Radiofrequency Ablation. <i>Oncology</i> , 2011, 80, 278-288.	0.9	67
120	Effect of aging on risk for hepatocellular carcinoma in chronic hepatitis C virus infection. <i>Hepatology</i> , 2010, 52, 518-527.	3.6	265
121	A predictive model of response to peginterferon ribavirin in chronic hepatitis C using classification and regression tree analysis. <i>Hepatology Research</i> , 2010, 40, 251-260.	1.8	58
122	Hepatic steatosis in chronic hepatitis C is a significant risk factor for developing hepatocellular carcinoma independent of age, sex, obesity, fibrosis stage and response to interferon therapy. <i>Hepatology Research</i> , 2010, 40, 870-877.	1.8	65
123	The presence of steatosis and elevation of alanine aminotransferase levels are associated with fibrosis progression in chronic hepatitis C with non-response to interferon therapy. <i>Journal of Hepatology</i> , 2008, 48, 736-742.	1.8	33
124	External validation of FIB-4: Diagnostic accuracy is limited in elderly populations. <i>Hepatology</i> , 2007, 47, 352-352.	3.6	10
125	Increased gene expression of water channel in cirrhotic rat kidneys. <i>Hepatology</i> , 1995, 21, 169-173.	3.6	101
126	Real-world long-term analysis of daclatasvir plus asunaprevir in patients with hepatitis C virus infection. <i>JGH Open</i> , 0, , .	0.7	1